• Mission: siRNAsense believes that scientific excellence and innovative research must be coupled with commercial strategy and best business practices
• Challenge: siRNA is a new class of drug candidates that are applicable to a broad range of different indications, each of which has its own challenges for therapeutics development
• Solution: siRNAsense together with the Active Advisory Group and their science teams bring a world class mix of talent, expertise, practice, vision and solutions to the unique challenges and goals the company is reaching for
• The siRNA-platform will deliver siRNA based drug candidates into the pipeline for the treatment of serious diseases within neuroscience and cancer.

siRNAsense will use its in-house expertise to:

Qualify projects for incorporation on the basis of IP considerations, project leadership and commercial potential. Projects should typically have already been approved by their respective TTOs.

Identify and optimize siRNA lead candidate drugs for pre-clinical development.

Facilitate commercialization of projects by identifying appropriate exit strategies, and entering into selective R&D and/or and licensing partnerships.

siRNAsense functions as a commercialization platform for RNAi-based biomedical research conducted at institutions in Norway:

• Biotechnology Centre of Oslo
• Centre for Molecular Biology and Neuroscience (CMBN)
• Rikshospitalet-Radiumhospitalet HF
• University of Oslo (UiO)